Zimmer Biomet (ZBH) Is Buying Pacira’s Iovera Device And Expanding Into Spasticity

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.

Zimmer Biomet Holdings (NYSE:ZBH) agreed to acquire Pacira BioSciences' FDA cleared iovera pain relief device. The agreement includes a collaboration between the companies to advance the iovera spasticity program. The transaction is expected to close in the third quarter of 2026, subject to customary conditions.

Zimmer Biomet operates as a large medical device company with a core focus on orthopedics and related surgical solutions. The planned addition of the iovera device extends its reach into non opioid pain management, an area where many hospitals and surgeons are looking for more treatment options.

For investors, this deal indicates that Zimmer Biomet is placing additional emphasis on pain and spasticity care that aligns with its existing joint and musculoskeletal portfolio. As the transaction moves toward its expected closing in the third quarter of 2026, attention may focus on how the company integrates iovera into its commercial channels and product ecosystem.

Stay updated on the most important news stories for Zimmer Biomet Holdings by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Zimmer Biomet Holdings.NYSE:ZBH Earnings & Revenue Growth as at Jul 2026

📰 Beyond the headline: 2 risks and 3 things going right for Zimmer Biomet Holdings that every investor should see.

Zimmer Biomet Holdings is using the iovera acquisition to widen its offering beyond implants into procedure-adjacent pain and spasticity care. With a deal value of up to US$140 million, including US$70 million upfront and future milestones, the price tag is modest relative to the company's US$2.75b of recently renewed revolving credit facilities. That liquidity provides room to fund transactions of this scale alongside other general corporate needs. Strategically, iovera can sit alongside Zimmer Biomet's joint replacement and extremities products, giving surgeons a non opioid option that fits within existing care pathways. The collaboration with Pacira on the spasticity program also points to a longer pipeline around neuromuscular conditions, rather than a single device purchase. For investors comparing Zimmer Biomet with peers such as Stryker and Johnson & Johnson's MedTech unit, this move reflects continued portfolio building around the full episode of care, not just the implant in the operating room. The key question is execution, including how quickly iovera can be integrated into Zimmer Biomet's sales force and whether clinician adoption justifies future milestone payments.

Story Continues

How This Fits Into The Zimmer Biomet Holdings Narrative

The iovera deal supports the narrative of Zimmer Biomet using acquisitions to broaden its offering around orthopedic procedures. It complements its focus on digital tools and robotics with perioperative pain and spasticity care. The transaction adds another integration task on top of other deals mentioned in the narrative. This could pressure margins and execution if commercialization of iovera and the spasticity program is slower or more complex than expected. The collaboration aspect and the non opioid pain focus are not fully captured in the previous emphasis on robotics and joint replacement. Investors may want to factor in this tilt toward broader perioperative solutions when thinking about the company's long term story.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Zimmer Biomet Holdings to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

⚠️ Execution risk as Zimmer Biomet integrates iovera and advances the spasticity program while also managing other acquisitions and maintaining its consolidated indebtedness to EBITDA within agreed credit facility covenants. ⚠️ Competitive risk if companies like Stryker or Johnson & Johnson offer alternative non opioid pain or neuromodulation solutions that gain stronger traction with hospitals and surgeons. 🎁 Potential for a broader pain management and spasticity portfolio that can deepen Zimmer Biomet's role across the full episode of orthopedic and neuromuscular care, not just implant sales. 🎁 Financial flexibility from the US$1.5b five year and US$1.25b 364 day revolving credit facilities, which can support measured M&A and commercialization efforts around devices like iovera.

What To Watch Going Forward

From here, investors may want to watch how Zimmer Biomet reports on iovera adoption within its orthopedic and sports medicine franchises, including any commentary on surgeon uptake and procedure volumes. Updates on the spasticity collaboration with Pacira will also matter, as they indicate whether this becomes a meaningful neuromuscular platform or remains a niche program. On the financing side, tracking leverage against the indebtedness to EBITDA covenant and any drawdowns on the US$2.75b of revolving credit could provide clues about how aggressively Zimmer Biomet is funding acquisitions and growth projects off its balance sheet.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Zimmer Biomet Holdings, head to the community page for Zimmer Biomet Holdings to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ZBH.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments